The Combination of Neuropsychiatric Symptoms and Blood-based biomarkers for Early Detection of Cognitive Disorders

*The submission is a preprint.

*The paper is under review at Molecular Neurodegeneration.

Yi Jin Leow (PGDip)¹, Zahinoor Ismail (MD, FRCPC)^{6,7}, Seyed Ehsan Saffari (PhD)⁴, Gurveen Kaur **Sandhu**(PhD)¹, Pricilia **Tanoto** (MSc)¹, Faith Phemie Hui En **Lee** (BA)¹, Smriti **Ghildiyal** (BA)¹, Shan Yao Liew (BA)¹, Gursimar **Bhalla** (BSc)¹, Sim Xin Ying (BSc)¹, Adnan Azam Mohammed (BEng)¹, Ashwati **Vipin**(PhD)¹, Chao **Dang** (MD, PhD)⁵, Nagaendran **Kandiah** (MD, FRCP)^{1,2,3,4}

 Dementia Research Centre (Singapore), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore Neuroscience and Mental Health Programme, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore National Healthcare Group, Singapore Duke-NUS Medical School, National University of Singapore, Singapore The First Affiliated Hospital, Sun Yat-sen University, China Hotchkiss Brain Institute, University of Calgary, Canada University of Exeter Faculty of Health and Life Sciences and NIHR Exeter Biomedical Research Centre, Exeter UK

Corresponding Author: Associate Professor Nagaendran Kandiah

Address: Lee Kong Chian School of Medicine, Nanyang Technological University, 11 Mandalay Rd, Singapore 308232

Tel: 65 65922653

Email: nagaendran_kandiah@ntu.edu.sg

Abstract

Background: Integrating behavioural assessments with blood-based biomarkers (BBM) could improve diagnostic accuracy for Mild Cognitive Impairment (MCI) linked to early-stage neurodegenerative disease (NDD). This study investigates the potential of combining neuropsychiatric symptoms (NPS) with BBM to enhance the differentiation between older adults with MCI and those with Normal Cognition (NC) in a multi-ethnic Southeast Asian cohort.

Methods: This cross-sectional study analyzed baseline data from the Biomarkers and Cognition Study, Singapore(BIOCIS). Data from 678 participants (mean[SD]age 59.16[11.02]years, 39.50% males) with NC and MCI were included. Behavioral symptoms were assessed using the Mild Behavioral Impairment Checklist (MBI-C) and Depression, Anxiety, and Stress Scales (DASS). Blood samples were analyzed for amyloid-beta (Aβ40, Aβ42), phosphorylated Tau (p-tau181), neurofilament light (NfL) and glial fibrillary acidic protein (GFAP). Regression models adjusted for age, education, gender, cognitive status (CS) and APOE-ε4 status were used. Discriminative power was evaluated using the area under the curve (AUC) to assess the combined predictive accuracy of behavioral and biological markers for CS, i.e., MCI status over CN.

Results: The study included MBI-C scores (total, interest, mood, control) and BBM levels (Aβ40, NfL, GFAP) were significantly higher in MCI group, compared to CN group. Elevated GFAP (OR:3.636, 95% CI:1.959, 6.751, p<0.001) and higher MBI-C-Mood scores (OR:2.614, 95% CI:1.538, 4.441, p<0.001) significantly increased the likelihood of MCI. The combined model, integrating NPS and BBM markers, showed strong discriminative ability for MCI ($AUC = 0.786$), with 64.7% sensitivity and 84.9% specificity at a threshold of 0.616, compared to NPS markers (AUC: 0.593) or BBM (AUC: 0.697) alone.

Conclusions and Relevance: The combined use of BBM and NPS achieved optimal accuracy in distinguishing MCI from NC, with strong associations between GFAP, MBI-C Mood scores, and CS. These findings underscore neuroinflammation and mood disturbances as critical factors in early NDD, supporting the importance of dual-dimension screening strategies. Integrating NPS and BBM represents a novel and effective diagnostic approach for detection of MCI due to AD or other dementias. The integrated framework, leveraging both pathophysiological and neuropsychiatric markers, facilitates earlier diagnosis, potentially improving clinical decision-making and enabling targeted disease-modifying therapies for individuals with neurodegenerative disorders.

Keywords: mild behavioral impairment, neurodegenerative disorders, mild cognitive impairment

Background

With the advancement of dementia treatments comes the responsibility to leverage biomarkers to identify cognitive impairment secondary to neurodegenerative disease (NDD) accurately at earlier stages. Plasma-derived and behavioural-biomarkers could play a crucial role for the early detection of NDD-related cognitive impairment, offering both accessibility and a holistic perspective on mechanistic and pathological changes, as well as observable symptoms, that occur during the onset of cognitive decline(CD). Current research demonstrates the value of blood-based biomarkers(BBM) in detection of NDD, enhancing traditional assessment tools such as neuropsychological assessments, positron emission tomography(PET) scans and neuroimaging.

The integration of behavioral-biomarkers—especially those reflecting mood and personality changes—can add significant diagnostic precision for Alzheimer's disease(AD) and related dementias. Neuropsychiatric symptoms(NPS) are non-cognitive, behavioral, or psychiatric symptoms that often accompany or precede CD(1). A notable subset of NPS is Mild Behavioral Impairment(MBI), characterized by the later-life onset of persistent behavioral symptoms that represent change from baseline, which has emerged as a reliable predictor of CD and incident dementia(2–4). The Mild Behavioral Impairment Checklist(MBI-C) was developed explicitly to measure MBI, and comprises five domains including decreased motivation, emotional dysregulation, impulse dyscontrol, social inappropriateness, and abnormal perception or thoughts(5). Current research demonstrates that the MBI-C effectively distinguishes NPS linked to to NDD from NPS related to psychiatric or stress-related etiologies, thereby enhancing dementia risk assessment(6–8). Complementarily, the Depression, Anxiety, and Stress Scales(DASS) (9) provide a comprehensive evaluation of mood symptoms in dementia increasingly recognized as early indicators of CD(10,11). Together, the MBI-C and DASS offer a holistic approach, capturing a broad spectrum of behavioural and psychological changes that correlates with cerebrospinal fluid(CSF)(12), plasma biomarkers(13,14), and cognitive impairment(15,16).

In parallel with behavioral assessments, BBM are transforming AD diagnosis by providing a minimally invasive and accessible alternative to traditional CSF and PET biomarkers(17–21). Recent research shows that BBM achieve high accuracy in predicting clinical decline in individuals with mild cognitive impairment(MCI), highlighting their potential as early indicators(22,23). A Swedish study confirmed that BBM targeting amyloid-beta and phosphorylated tau achieve diagnostic accuracy comparable to CSF and PET, with predictive values exceeding 90%, demonstrating their clinical utility in various care settings(24). Compared to CSF biomarkers, BBM offer significant practical advantages as they are highly scalable, less invasive and promote higher patient compliance. BBM are therefore more feasible for large-scale screening and triage in under-resourced settings, while facilitating the integration of anti-amyloid therapies into routine clinical practice(25).

Within the Amyloid, Tau, and Neurodegeneration(ATN) framework, amyloid-beta 42(Aβ42), amyloid-beta 40(Aβ40), and the Aβ42/Aβ40 ratio are key markers of amyloid plaque accumulation, a defining feature of AD pathology(26,27). For tau pathology, phosphorylated Tau 181(p-tau181) serves as a marker for neurofibrillary tangles associated with AD progression (28–30). Additionally, Neurofilament light(NfL) provides insights into neuroaxonal damage, while Glial fibrillary acidic protein (GFAP) is associated with reactive astrogliosis and neuroinflammation(31–33). Alongside these ATN biomarkers, genetic factors such Apolipoprotein E ε4(APOE4) genotype play a critical role in AD risk and biomarker expression. APOE4 is strongly linked to increased amyloid-beta accumulation and is one of the most significant genetic risk factors for late-onset AD. Notably, populations in Southeast Asia exhibit a lower prevalence of APOE4 compared to Western populations (34), potentially explaining differences in amyloid positivity, CD rates, and dementia types observed between these groups (35). Recently, the European Medicines Agency, stipulated that lecanemab could not be prescribed in APOE4 homozygotes, further supporting its importance (36). Together, these BBM and blood-based genetic factors provide a multifaceted view of neurodegeneration, offering deeper insights into CD and AD risk and progression.

Given the capacity to capture diverse aspects of neurodegeneration, BBM hold significant potential for elucidating the relationship between behavioral symptoms and the progression of NDD. The link between NPS and BBMs is still emerging, with research to date yielding mixed results. For instance, in a large population-based study, no difference in AD risk was observed between APOE4 carriers and non-carriers among Americans without baseline depression(37). For amyloid-related biomarkers, amyloid-beta has been more extensively studied in relation to behavioral symptoms, particularly depression(38). A study in Vienna reported that higher baseline plasma Aβ42 levels predicted incident depression and conversion to AD over five years(39). Similarly, the Rotterdam Study reported cross-sectional links between high Aβ40 and depressive symptoms in prodromal dementia, but longitudinally associated lower Aβ40 and Aβ42 with increased depression risk in elderly individuals without dementia, indicating a complex role of Aβ peptides in the etiology of depression(40). For tau biomarkers, elevated plasma p-tau181 has been associated with NPS such as appetite changes and disinhibition(41). Regarding neurodegeneration biomarkers, NfL has shown promise as a marker for multiple NPS, including aberrant motor behavior, anxiety, sleep disturbances and euphoria(42). GFAP, another marker of neurodegeneration, has been associated with depression(43).

Focusing on MBI, characterized by late-life emergent and persistent NPS, findings consistently link it to key BBM in the ATN framework. For amyloid-related biomarkers, global MBI status and MBI affective dysregulation demonstrated associations with amyloid-beta(44). In terms of tau pathology, recent findings by Ghahremani(13) indicate MBI correlates with elevated plasma p-

tau181 levels and a nearly fourfold increased risk of dementia, with higher baseline and longitudinal increases in p-tau181 in individuals with MBI compared to those without MBI. Additionally, Gonzalez \Box Bautista(14) linked MBI domains, such as impulse dyscontrol and emotional dysregulation, to p-tau181 and metabolic biomarkers, implicating tau alongside metabolic disruption in preclinical and prodromal AD. In neurodegeneration, findings from the Alzheimer's Disease Neuroimaging Initiative(ADNI) cohort revealed that in preclinical and prodromal samples, MBI and its interaction with time predict NfL changes, indicating MBI as an early marker of accelerated neurodegeneration and CD(45). Collectively, these studies illustrates MBI's value as an early marker of AD pathology and dementia risk.

The growing research on BBM, MBI, and NPS at early stages of CD underscores their potential for early disease detection. When combined, these markers offer a multifaceted approach to early diagnosis, capturing both pathobiological and psychological dimensions of dementia onset. Despite this prospect, a comprehensive study systematically combining these markers for detecting cognitive impairment has, to our knowledge, not yet been conducted.

This study evaluates the predictive utility of BBM and behavioral-biomarkers in distinguishing persons with MCI from those with normal cognition. By systematically analyzing MBI-C, DASS and BBM in a multi-ethnic Southeast Asian cohort, we assess the combined value of these measures for higher diagnostic accuracy for MCI linked to NDD and to explore underlying mechanisms of cognitive impairment.

Methods

Participants

Participants were drawn from the Biomarkers and Cognition Study, Singapore(BIOCIS), a 5 year longitudinal study with annual assessments. Recruitment is community-based, targeting individuals aged 30 to 95 years in Singapore. To explore how pathology presents with or without minimal clinical symptoms, both cognitively impaired and unimpaired individuals are included. Participants were classified as Cognitively Normal(CN) or as having MCI based on Peterson's(46) criteria and National Institute on Aging-Alzheimer's Association(NIA-AA) guidelines(47) after completion of a validated neuropsychological test battery. Further study design and methodological details are available in the BIOCIS protocol paper(48).

Blood based biomarkers

Venepuncture was performed by a certified phlebotomist at baseline study visit. Blood samples were collected in EDTA vacutainers, left at room temperature for 30 minutes, then centrifuged at 2000 g for 10 minutes at 4°C. The resulting plasma was aliquoted and stored at –80°C. Genomic DNA was extracted from whole blood samples, collected into EDTA vacutainers(Becton Dickinson) using the QIAamp DNA Blood Maxi Kit(Qiagen). The concentration and purity of the DNA were assessed using a Nanodrop One spectrophotometer (Thermo Fisher Scientific, United Kingdom). DNA was analysed using either the StepOne plus or QuantStudio 7 Pro Real-Time Polymerase Chain Reaction analyser(Applied Biosystems) to determine the allelic variants of APOE. APOE genotypes were determined using SNPs rs429358 and rs7412(Life Technologies), as per manufacturer's protocol, using a 96-well MicroAmp Fast(StepOne Plus)/Optical(Quanstudio) reaction plate(Life Technologies), with 10ng of DNA and either one of the 2 SNPs, in a 10ul TaqPath ProAmp master mix reaction(Applied Biosystems)(49,50). Results were analysed using the Design and Analysis 2.5.1 Real Time PCR system software(Applied Biosystems) and respective APOE genotype were rated independently by raters. Quanterix's Single Molecule Array(Simoa) digital biomarker technology platform was used to quantify all plasma biomarkers(NfL, GFAP, Aβ40, Aβ42, ptau181)(Quanterix, Billerica, MA, USA). The Neurology 4-PlexE(NfL, GFAP, Aβ40, Aβ42) and ptau181 Advantage V2.1 kits were utilized for expression analysis on the HD-X Analyzer platform(Quanterix, Billerica, MA, USA) in accordance with manufacturer's protocol(51).

Behavioural profiles and Neuropsychiatric symptoms

Self-reported questionnaires were administered including MBI-C and DASS. The MBI-C(5) evaluates MBI across five NPS domains: Mood/Anxiety, Apathy/Drive, Impulse Dyscontrol, Social Inappropriateness, and Abnormal Perception/Thought Content, with symptoms required to persist for at least six months and represent a change from longstanding baseline. The DASS(9) assesses depression, anxiety, and stress over a one-week timeframe.

Statistical Analyses

Continuous variables were summarized using mean and standard deviation, while categorical variables were described using frequency and percentages. To address skewness, logarithmic transformations were applied to blood and behavioral data, with a constant of 1 added to continuous variables that included values below 1. Two independent sample t tests were employed to compare continuous variables between the CN and MCI groups. Categorical variables were compared between CN and MCI using Chi-square test.

Logistic regression models were performed to investigate the association of baseline characteristics and cognitive diagnosis(MCI vs CN) while adjusting for age, years of education, gender and APOE status. The results were reported as odds ratio(OR), 95% confidence interval(CI), and p value. A dual-regression approach was implemented, consisting of two multivariable logistic regression models with cognitive status(MCI vs CN) as outcome. The first regression(Model 1), included behavioral parameters only as continuous variable predictors and the second(Model 2) included BBM only as continuous variables, both adjusted for demographic variables and APOE status. Within each model, a backward variable selection approach identified variables independently associated with cognitive diagnosis. Subsequently, the shortlisted variables from both models were included in a final multivariable logistic regression model(Combined Model), adjusted for demographic variables and APOE status. Further, overall discriminative power of the final model was assessed via area under the curve(AUC) analyses with model performance evaluated using Hosmer and Lemeshow lack-of-fit test. For all models, variance inflation factor statistics and independence of errors were utilized to confirm the absence of multi-collinearity among predictor variables.

To further understand the association between behavioral parameters, cognitive diagnoses, and BBM, additional logistic regressions were implemented. Predictors were behavioural-biomarkers as continuous variables, adjusting for demographics, APOE status, and cognitive diagnosis (Model 4). Outcomes were blood biomarker status(i.e., high vs low), based on dichotomization using a median split (52,53).

All statistical analyses were conducted using IBM SPSS Statistics, Version 29.0(Armonk,NY:IBM Corp.), with statistical significance set as p<0.05 unless otherwise specified.

Results

Demographics

678 participants were recruited. The MCI group was older $(p<.001)$ and had fewer years of education (p<0.001). For behavioral assessments, MBI-C-Total scores were higher in the MCI group (p=0.006), with significant differences in the interest ($p=0.005$), mood ($p=0.005$), and control ($p=0.009$) subdomains. Additionally, BBM analyses showed higher mean levels of A β 40 (p< 0.001), NfL (p< 0.001), and GFAP (p< 0.001) in the MCI group compared to the CN. Table 1 summarizes the BIOCIS demographic variables alongside behavioral and BBM data.

Table 1. Participant demographics, behavioural phenotype, and blood biomarker levels by cognitive diagnosis

Note. \dagger = mean \pm Standard Deviation, \Box = Frequency (percentages)

* Comparing the two groups using two-independent sample t-test (or Mann-Whitney U test, depends on normality) for continuous variables or Chi-square (or Fisher's exact test, where appropriate) for categorical variables

Abbreviations: APOE = Apolipoprotein E, $A\beta$ = Amyloid Peptides, p-tau181 = Phosphorylated Tau at position 181, GFAP = Glial fibrillary acidic protein, NfL =Neurofilament Light Chain

Behavioral and BBM as Independent Predictors of MCI Over CN

Table 2 summarizes the results of the multivariable logistic regression analyses, detailing significant behavioral and blood-based predictors of MCI over CN. In the behavioural model(Model 1), for each 1-point increase in the MBI-C-Mood subdomain, the odds of having MCI over being CN increased by approximately 59%(OR:1.587, 95% CI: 1.127–2.236, p=0.008). Similarly, for each 1point increase in the DASS Depression score, the odds of MCI over CN increased by 25%(OR:1.250, 95%CI: 1.013–1.542, p=0.037). In contrast, higher DASS-Stress scores were inversely associated with cognitive impairment, with each 1-point increase in DASS-Stress reducing the odds of MCI by 20%(OR:0.800, 95%CI: 0.660–0.970, p=0.023). The AUC for behavioral-markers alone was 0.593(95%CI: 0.55–0.636).

Among BBM(Model 2), elevated NfL and GFAP levels were strongly associated with the likelihood of being classified as MCI over CN. Each unit increase in NfL corresponded to a 110% increase in MCI likelihood over CN(OR:2.096, 95% CI: 1.365–3.217, p=0.001). GFAP showed an even stronger association, with each unit increase raising the odds of MCI over CN by approximately 199%(OR:2.987, 95%CI: 1.913–4.664, p<0.001).

Table 2. Multivariable Logistic Regression Analysis of Key Behavioral and Blood Biomarkers as Predictors of Cognitive Diagnosis

Abbreviations: MBI-C = Mild Behavioural Impairment-Checklist, DASS = Depression Anxiety Stress Scales, NfL =Neurofilament Light Chain, GFAP = Glial fibrillary acidic protein

Combined Model of Predictive Value of Behavioral Scores and Blood Biomarker Levels for Cognitive Status

In the behavioural and blood model(Combined Model), variables from Table 2(i.e.,variables from the Model 1 and 2 meeting statistical significance) were included along with demographics and APOE status as clinical confounders. Higher GFAP(OR:3.636, 95%CI: 1.959–6.751, p< 0.001) and MBI-C-Mood(OR:2.614, 95%CI: 1.538–4.441, p< 0.001) significantly increased the likelihood of MCI by 263.6% and 161.4% respectively. The model AUC was 0.786(95%CI: 0.744–0.827), surpassing separate models based on either behavioral-markers(AUC:0.593, 95%CI: 0.55–0.636) or BBM(AUC:0.697, 95%CI: 0.658–0.736). At an optimal threshold of 0.616, the Combined model achieved 64.7% sensitivity and 84.9% specificity, demonstrating strong discriminatory ability in distinguishing between CN and MCI individuals(Figure 1).

Figure 1. Receiver Operating Characteristic (ROC) Curves Comparing Different Models for Distinguishing Between Cognitively Normal and Mild Cognitive Impairment Groups

Behavioural and Cognitive Diagnoses in Association with Dichotomized BBM Levels

For Model 4, with continuous behaviour scores as predictors and biomarker status as binary outcome, a higher MBI-C-Total score was significantly associated with odds of high Aβ⁴² status(OR:1.437, 95%CI: 1.127–1.831, p=0.003). Specific MBI-C subdomains were significantly linked to likelihood of high Aβ42: MBI-C-Interest(OR:1.800, 95%CI: 1.139–2.845, p=0.012), MBI-C-Mood (OR:1.587, 95%CI: 1.068–2.359, p=0.022), and MBI-C-Control(OR:1.782, 95%CI: 1.242– 2.557, p=0.002). Higher DASS-Stress scores were significantly associated with likelihood of high ^Aβ40 levels (OR:1.252, 95%CI: 1.039–1.508, p=0.018). MBI-C-Total score was associated with likelihood of high p-tau181(OR:1.279, 95%CI: 1.001–1.634, p=0.049). Additionally, higher DASS-Depression scores(OR:1.302, 95%CI: 1.061–1.598, p=0.012) and higher DASS-Stress scores $(OR:1.238, 95\%CI: 1.020-1.503, p=0.031)$ significantly increased the odds of high p-tau181. Lastly, higher DASS-Anxiety scores were marginally associated with probability of high GFAP levels(OR:1.260, 95%CI: 1.000–1.587, $p=0.05$). Table 3 presents a detailed summary of these results.

Table 3. Multivariate Logistic Regression Analysis of Behavioral-Biomarkers in Relation to Blood Biomarkers

Abbreviations: MBI-C = Mild Behavioural Impairment-Checklist, DASS = Depression Anxiety Stress Scales, p-tau181 = Phosphorylated Tau at position 181, NfL =Neurofilament Light Chain Aβ = Amyloid Peptides, GFAP = Glial fibrillary acidic protein

[†] Odds ratio (95% CI), \degree p<0.05, \degree p<0.005, significant p values are bolded.

Discussion

Integration of Biomarkers for Early Detection of Cognitive Impairment

 $\begin{array}{c} \n\end{array}$ The results demonstrate that integrating blood-based and behavioral measures enhances prediction of MCI status compared to using either measure alone. Specifically, models that combine both BBM and behavioral data demonstrate the highest accuracy in identifying MCI status, with BBM alone outperforming behavioral measures when used in isolation. These findings present three key insights: behavioral measures contribute to cognitive status prediction and correlate with BBM, BBM alone serve as robust predictors of MCI, and the combined model provides superior predictive power over individual approaches.

Behavioural-biomarkers as Indicators of MCI status

Higher scores on the MBI-C-Total and subdomains—specifically Interest, Mood, and Control—were linked to increased likelihood of MCI. The robust association between mood disturbances and cognitive impairment is particularly compelling, as mood symptoms often precede CD and reflect underlying disruptions in neural circuits involved in emotional regulation**(54,55)**. Interestingly, lower DASS Stress scores were inversely associated with cognitive impairment, possibly because moderate stress enhances attention and memory, consistent with the Yerkes-Dodson law**(56)**. Collectively, these findings underscore that behavioral and mood-related symptoms may not only serve as early predictors but also actively contribute to the acceleration of CD. This assertion is well-supported by prior research on the prodromal stages of AD, which suggests early NPS play a significant role in modulating the disease's trajectory**(57–59)**.

Behavioural-Biomarkers as Early Indicators of Neurodegeneration

Higher MBI-C scores were significantly associated with elevated Aβ42 levels, particularly within the subdomains of Interest, Mood, and Control, supporting the role of early behavioral disturbances as clinical indicators of amyloid-related pathology(12,44,60,61). Moreover, higher DASS-Stress scores were strongly associated with elevated Aβ40 levels, reinforcing evidence of an association between stress and amyloid pathology($62,63$). The inconsistent findings for A β 42 and the ^Aβ42/Aβ40 ratio in our study and throughout literature highlight variability likely attributable to differences in study cohorts and methodological heterogeneity, underscoring the complexity of utilizing amyloid biomarkers for prediction of CD.

Furthermore, elevated MBI-C Total scores, DASS-Depression and DASS-Stress scores were significantly linked to higher p-tau181 levels, aligning with emerging evidence that behavioral

s
i
l symptoms may correlate with tau pathology**(12–14,64,65)**. This relationship illustrates the potential interplay between stress, depression, and tau-related neurodegeneration, which is critical for understanding the broader neuropathological mechanisms underlying CD. Finally, the marginal association between elevated GFAP levels and DASS-Anxiety scores suggests a tentative link between anxiety and neuroinflammatory processes, potentially reflecting glial activation in response to chronic psychological distress.

Plasma Biomarkers and MCI status

Our results demonstrate the potential of BBM to distinguish MCI from CN participants, reinforcing their value in early detection of AD and related cognitive disorders.

Amyloid Pathology and Early Detection

Although the Aβ42/40 ratio did not significantly differ between the CN and MCI groups, the elevated Aβ40 levels in MCI participants suggest early amyloid dysregulation. Aβ40, which is increasingly implicated in amyloid plaque formation and neurotoxicity, may serve as an early biomarker of amyloid pathology despite historically receiving less attention than Aβ42(66). This pattern aligns with recent research indicating that $\Delta\beta$ 40 elevations may precede $\Delta\beta$ 42 changes(67), supporting its potential as an early biomarker of amyloid-related pathology.

Tau

In contrast, p-tau181 did not differ significantly between cognitive groups nor predict MCI status. Although tau pathology is central to AD, plasma p-tau181 may have lower sensitivity to early cognitive impairment compared to markers of amyloid dysregulation or neuroinflammation(68). This corresponds with recent findings that p-tau181 becomes more relevant in later AD stages as tau pathology accumulates in the medial temporal cortex and spreads to other cortical regions(69,70).

Neurodegeneration

NfL emerged as a robust marker of neurodegeneration, strongly associated with MCI status. Its high sensitivity to axonal damage makes it valuable for detecting preclinical neurodegeneration and tracking the MCI-to-AD transition(71–73). This study supports NfL's role as a core biomarker for monitoring disease progression and evaluating neuroprotective therapies(74).

Neuroinflammation

 $\frac{1}{1}$ The significant elevation of GFAP levels in MCI participants reinforces its role as a biomarker of neuroinflammation, specifically astrocytic activation(75). Our results suggest that neuroinflammation, a key driver of AD pathology, may precede or exacerbate AD-related changes, contributing to CD via oxidative stress, cytokine release, and neuronal damage(76,77). Detecting neuroinflammation through GFAP may enable early intervention strategies aimed at modulating these pathways before significant neuronal loss occurs.

Enhanced Predictive Power through Integrated Models

Our results show that integrating BBMs with behavioral assessments provides a comprehensive view of early pathological changes in CD, offering insights beyond traditional cognition-based models. The combined model demonstrated notably superior discriminative power (MCI vs. CN) compared to models using behavioral or BBM alone, emphasizing the value of capturing both pathobiological changes and NPS. Notably, GFAP and MBI-C Mood emerged as the most robust predictors of MCI, supporting addressing both neuroinflammatory processes and moodrelated symptoms in early detection strategies.

The Role of Neuroinflammation and Behavioral Changes

The prominent role of GFAP in our findings emphasizes neuroinflammation as a key process in early pathogenesis of AD and other dementias. Elevated GFAP levels, reflecting astrocytic activation, are increasingly recognized not only as markers of neurodegeneration but as contributors to disease progression via cytokine release and reactive gliosis, actively drive neuroinflammatory responses that exacerbate neuronal injury and accelerate CD**(78,79)**. Consequently, GFAP emerges as a critical biomarker for early detection, particularly in individuals with subtle cognitive changes at high risk for progression.

The significant predictive value of MBI-C-Mood scores emphasizes the role of mood disturbances as early indicators of neurodegeneration. Rather than psychological consequences of cognitive impairment, mood disturbances may reflect underlying neuropathological changes**(80–82)**. The association between elevated mood scores, p-tau181, and GFAP links emotional dysregulation to biological markers of neurodegeneration, particularly in the prefrontal cortex and hippocampus regions vulnerable to early AD pathology**(83)**. These findings affirm the interplay between mood disturbances and the biological processes driving CD.

Limitations

 $\begin{array}{c} \n\text{I} \n\end{array}$ As with most studies, there are limitations. The exclusion of participants with severe psychiatric diseases may limit the generalizability of our findings, as this group could provide crucial insights into early cognitive changes. Importantly, severity of psychiatric symptoms is often used as a proxy for psychiatric disorders, potentially overlooking neurodegeneration underlying some NPS. The cross-sectional design further restricts our ability to infer causality or track changes over time. The relatively small sample size also limits statistical power and generalizability to larger populations. Future longitudinal studies, such as those planned within the expanded BIOCIS cohort, will be essential to validate these associations, elucidate temporal relationships between NPS, BBM and CD. Finally, translating these findings into clinical practice will require research focused on validating biomarker mechanisms, assessing predictive value for disease progression, and ensuring the scalability, cost-effectiveness, and accessibility of biomarker assays for real-world implementation.

Conclusions

This study accentuates the value of integrating biological markers with behaviouralbiomarkers to deepen our understanding of early neurodegeneration and CD. Elevated GFAP and MBI-C Mood scores emerged as robust indicators of cognitive impairment, spotlighting the vital roles of neuroinflammation and mood disturbances. This integrative approach holds significant potential to enhance early detection of cognitive impairment, refine intervention strategies for at-risk populations, and improve outcomes through timely intervention.

The combination of self-reported MBI assessments with BBM provides enhanced diagnostic utility, enabling a more nuanced understanding of NDD progression. As precision medicine gains prominence, such integrative models can inform clinical decision-making and enable targeted diseasemodifying therapies for individuals with neurodegenerative disorders. By establishing a framework that incorporates NPS, MBI, and BBM into diagnostic protocols, this research supports targeted therapeutic interventions and has the potential to transform dementia diagnosis, monitoring, and care.

List of abbreviations

NDD - Neurodegenerative Disease CD - Cognitive Decline BBM - Blood-Based Biomarkers PET - Positron Emission Tomography AD - Alzheimer's Disease NPS - Neuropsychiatric Symptoms MBI - Mild Behavioral Impairment

- $\begin{array}{c} \mathbf{I} \\ \mathbf{I} \\ \mathbf{I} \end{array}$ MBI-C - Mild Behavioral Impairment Checklist
- DASS Depression, Anxiety, and Stress Scales
- CSF Cerebrospinal Fluid
- MCI Mild Cognitive Impairment
- ATN Amyloid, Tau, and Neurodegeneration
- ^Aβ42 Amyloid-Beta 42
- ^Aβ40 Amyloid-Beta 40
- p-tau181 Phosphorylated Tau at position 181
- NfL Neurofilament Light
- GFAP Glial Fibrillary Acidic Protein
- APOE4 Apolipoprotein E ε⁴
- ADNI Alzheimer's Disease Neuroimaging Initiative
- BIOCIS Biomarkers and Cognition Study, Singapore
- CN Cognitively Normal
- NIA-AA National Institute on Aging-Alzheimer's Association
- EDTA Ethylenediaminetetraacetic Acid
- SNPs Single Nucleotide Polymorphisms
- PCR Polymerase Chain Reaction
- Simoa Single Molecule Array
- AUC Area Under the Curve
- ROC Receiver Operating Characteristic

Article Information

Corresponding Author: Nagaendran Kandiah, Lee Kong Chian School of Medicine, Nanyang Technological University, 11 Mandalay Rd, Singapore 308232 (nagaendran_kandiah@ntu.edu.sg)

Author Contributions: Yi Jin Leow had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Yi Jin Leow

(
(
(*Acquisition, analysis, or interpretation of data:* Yi Jin Leow, Zahinoor Ismail, Seyed Ehsan Saffari, Gurveen Kaur Sandhu, Pricilia Tanoto, Faith Phemie Hui En Lee, Smriti Ghildiyal, Shan Yao Liew, Gursimar Bhalla, Sim Xin Ying, Adnan Azam Mohammed, Ashwati Vipin, Chao Dang, Nagaendran Kandiah

Drafting of the manuscript: Yi Jin Leow, Zahinoor Ismail, Seyed Ehsan Saffari, Nagaendran Kandiah

Statistical analysis: Yi Jin Leow, Seyed Ehsan Saffari

Supervision: Nagaendran Kandiah

Funding: This study received funding support from the Strategic Academic Initiative grant from the Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; National Medical Research Council, Singapore under its Clinician Scientist Award (MOH-CSAINV18nov-0007); Ministry of Education, Singapore, Academic Research Fund Tier 1 (RT02/21); and Ministry of Education, Singapore, Science of Learning Grant (MOESOL2022-0002).

Conflict of Interest Disclosures: All authors declare no competing interests.

Acknowledgements: The authors express their gratitude to all individuals who are currently or will be participating in research at the Dementia Research Centre (Singapore).

Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available due to ethical restrictions, but are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Informed consent was obtained from all participants according to the Declaration of Helsinki and local clinical research regulations, and procedures used in the study were in accordance with ethical guidelines. This study has been approved by the NTU Institutional Review Board (NTU-IRB-2021- 1036), and procedures used in the study were in accordance with ethical guidelines.

Consent for publication

 $\frac{1}{2}$ All authors have reviewed and approved the contents of the final manuscript contents and provided consent for its publication.

References

-
- 1. Morther, M. Hammedgella R, Hammedgella R, Marchesty, Andreasty, Parameter, Paperton and Cognitive Impairment: Understanding the Importance of Co-Morbid Symptoms. Journal of Alzheimer's Disease. 2017;59(1):141–53.
2. Cre Commert's Disease. 2017;59(1):141–53.
Alzheimer's Disease. 2017;59(1):141–53.
Creese B, Brooker H, Ismail Z, Wesnes KA, Hampshire A, Khan Z, et al. Mild behavioral
impairment as a marker of cognitive decline in cognitively Creese B, Brooker H, Ismail Z, Wesnes KA,
impairment as a marker of cognitive decli
Journal of Geriatric Psychiatry. 2019;27(8 impairment as a marker of cognitive decline in cognitively normal older adults. The An
Journal of Geriatric Psychiatry. 2019;27(8):823–34.
Million Behavioral behavior. The An Final of Geriatric Psychiatry. 2019;27(8):823–34. Journal of Geriatric Psychiatry. 2019;27(8):823–34.
- $\frac{1}{2}$
- 3. Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, et al. The Mild Behavioral
3. Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, et al. The Mild Behavioral
5. Ismail Z, Agüer 2021;80(1):459–69.
McGirr A, Nathan S, Ghahremani M, Gill S, Smith EE, Ismail Z. Progression to dementia or
reversion to normal cognition in mild cognitive impairment as a function of late-onset
neuropsychiatric symptoms. McGirr A, Nathan S,

reversion to normal

neuropsychiatric syn

Ismail Z, Agüera-Orti

Impairment Checklis

populations. Journal
- reversion to normal cognition in mild cognitive impairment as a function of late-onset
neuropsychiatric symptoms. Neurology. 2022;98(21):e2132–9.
5. Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, e neuropsychiatric symptoms. Neurology. 2022;98(21):e2132–9.
Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, et al. The Mild B
Impairment Checklist (MBI-C): a rating scale for neuropsychiatric symptom
- Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fisch
Impairment Checklist (MBI-C): a rating scale for neuropsychiatr
populations. Journal of Alzheimer's disease. 2017;56(3):929–38
Ismail Z, Smith EE, Geda Y, S 5. Ismail Z, Aguera-Ortiz L, Aguera-Ortiz L, Aguera-Ortiz L, Aguera-Ortiz L, Aguera-Ortiz L, Aguera-Ortiz L, Brodaty H, Smith G, et al. Neuropsychiatric symptoms as

16. Ismail Z, Smith EE, Geda Y, Sultzer D, Brodaty H, Sm populations. Journal of Alzheimer's disease. 2017;56(3):929–38.
Ismail Z, Smith EE, Geda Y, Sultzer D, Brodaty H, Smith G, et al. Neuropsychiatric symptoms as
early manifestations of emergent dementia: provisional diagnost populations. Journal of Alzheimer's Comail 2, Smith EE, Geda Y, Sultzer D, Brodaty H, Smith G, et al. Netween the early manifestations of emergent dementia: provisional diagnost
impairment. Alzheimer's & Dementia. 2016;12(
- early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral
impairment. Alzheimer's & Dementia. 2016;12(2):195–202.
7. Leow Y, Soo SA, Kumar D, Zailan FZB, Sandhu GK, Vipin A, et al. Mild early mannert. Alzheimer's & Dementia. 2016;12(2):195–202.
Leow Y, Soo SA, Kumar D, Zailan FZB, Sandhu GK, Vipin A, et al. Mild Behavioral Impairment an
Cerebrovascular Profiles Are Associated with Early Cognitive Impairme impair of Network Cerebrovascular Profiles Are Associated with Early Cognitive
Southeast Asian Cohort. Journal of Alzheimer's Disease. 202
Matsuoka T, Ismail Z, Narumoto J. Prevalence of mild behavidementia in a psychiatri
-
- The Community State of Alzheimer's Disease. 2024; (Preprint): 1–9.

8. Matsuoka T, Ismail Z, Narumoto J. Prevalence of mild behavioral impairment and risk of

dementia in a psychiatric outpatient clinic. Journal of Alzheim Southeast Asian Cohort. Journal of Alzheimer's Disease. 2024;(Preprint):1–9.
Matsuoka T, Ismail Z, Narumoto J. Prevalence of mild behavioral impairment and risk of
dementia in a psychiatric outpatient clinic. Journal of Al Matsuoka T, Ismail Z, Narumoto J. Prevalence of mild behavioral impairment a
dementia in a psychiatric outpatient clinic. Journal of Alzheimer's Disease. 20
Lovibond PF, Lovibond SH. The structure of negative emotional sta 8. Matter in a psychiatric outpatient clinic. Journal of Alzheimer's Disease. 2019;70(2):56
8. Lovibond PF, Lovibond SH. The structure of negative emotional states: Comparison of th
19 Depression Anxiety Stress Scales (DAS dementia in a psychiatric outpatient chinese and entity the method of the
Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories.
Behaviour research and therapy. 1995;33(3):335–43.
Freire
-
- 9. Lowischer Princent Press Scales (DASS) with the Beck Depression and Anxiety Inventories

Behaviour research and therapy. 1995;33(3):335–43.

10. Freire ACC, Pondé MP, Liu A, Caron J. Anxiety and depression as longitudin Behaviour research and therapy. 1995;33(3):335–43.
Freire ACC, Pondé MP, Liu A, Caron J. Anxiety and depression as longitudinal predictors of m
cognitive impairment in older adults. The Canadian Journal of Psychiatry. 2017 Freire ACC, Pondé MP, Liu A, Caron J. Anxiety and dep
cognitive impairment in older adults. The Canadian Jo
Perin S, Lai J, Pase M, Bransby L, Buckley R, Yassi N, et
depression, anxiety, and cognition in middle-aged adu
ca 11. Perin S, Lai J, Pase M, Bransby L, Buckley R, Yassi N, et al. Elucidating the association between

11. Perin S, Lai J, Pase M, Bransby L, Buckley R, Yassi N, et al. Elucidating the association between

12. Ismail Z, Le
- Perin S, Lai J, Pase M, Bransby L, Buckley R, Yassi N, et al. Elucidating the association between
depression, anxiety, and cognition in middle-aged adults: Application of dimensional and
categorical approaches. Journal of 11. Perin S, Lai J, Perin S, Lai H, P, Pasini, P, P, P
depression, anxiety, and cognition in middle-aged adults: Application of dimensional and
categorical approaches depression, and cognition in different advertises. 2022;296:559-66.

Ismail Z, Leon R, Creese B, Ballard C, Robert P, Smith EE. Optimizing detection of Alzheime

disease in mild cognitive impairment: a 4-year biomarker stu Ismail Z, Leon R, Creese B, Ballard C, Robert P, Smith EE. Optimizing detect
disease in mild cognitive impairment: a 4-year biomarker study of mild be
ADNI and MEMENTO. Molecular Neurodegeneration. 2023;18(1):50.
Ghahreman
- 12. Islamin J. Leon R. Islamin J. Leon R. A. Chahremani M. Wang M. Chen HY. Zetterberg H. Smith E. Ismail Z. et al. Plasma phosphorylar tau at threonine 181 and neuropsychiatric ADNI and MEMENTO. Molecular Neurodegeneration. 2023;18(1):50.
Ghahremani M, Wang M, Chen HY, Zetterberg H, Smith E, Ismail Z, et al. Plasma phosphorylated
tau at threonine 181 and neuropsychiatric symptoms in preclinical a Ghahremani M, Wang M, Chen HY, Zetterberg H, Smith E, Ismail Z, et
tau at threonine 181 and neuropsychiatric symptoms in preclinical an
disease. Neurology. 2023;100(7):e683–93.
Gonzalez-Bautista E, Momméja M, de Mauléon A,
- 13. Chen Herberta 13. Ghadren and neuropsychiatric symptoms in preclinical and prodromal Alzheimer
disease. Neurology. 2023;100(7):e683–93.
14. Gonzalez-Bautista E, Momméja M, de Mauléon A, Ismail Z, Vellas B, Delrieu J, e tau at three neurology. 2023;100(7):e683–93.
Gonzalez-Bautista E, Momméja M, de Mauléon A, Ismail Z, Vellas B, Delrieu J, et al. Mild
behavioral impairment domains are longitudinally associated with pTAU and metabolic
biom Gonzalez-Bautista E, Momméja M, de Mau
behavioral impairment domains are longitudiomarkers in dementia-free older adults.
Creese B, Ismail Z. Mild behavioral impairm
marker of preclinical Alzheimer's disease. A behavioral impairment domains are longitudinally associated with pTAU and metabolic
biomarkers in dementia-free older adults. Alzheimer's & Dementia. 2024;
15. Creese B, Ismail Z. Mild behavioral impairment: measurement an
- biomarkers in dementia-free older adults. Alzheimer's & Dementia. 2024;
Creese B, Ismail Z. Mild behavioral impairment: measurement and clinical correlates of
marker of preclinical Alzheimer's disease. Alzheimer's research Creese B, Ismail Z. Mild behavioral impairment: measurement and clinical
marker of preclinical Alzheimer's disease. Alzheimer's research & therapy.
Gates N, Valenzuela M, Sachdev PS, Fiatarone Singh MA. Psychological we
wi
- 15. Cates N, Valenzuela M, Sachdev PS, Fiatarone Singh MA. Psychological well-being in individuals
16. Gates N, Valenzuela M, Sachdev PS, Fiatarone Singh MA. Psychological well-being in individuals
16. Gates N, Valenzuela manner of preclimical alternation of the current manner of the current allerapy. 2022;
Gates N, Valenzuela M, Sachdev PS, Fiatarone Singh MA. Psychological well-being in individual
with mild cognitive impairment. Clinical with mild cognitive impairment. Clinical interventions in aging. 2014;779–92. with mild cognitive impairment. Clinical interventions in aging. 2014;779–92.
- $\ddot{}$
- assessing cost-utility of integrating blood biomarkers in clinical practice for disease-modifying
treatment. The Journal of Prevention of Alzheimer's Disease. 2024;1–15.
18. Blennow K, Galasko D, Perneczky R, Quevenco F, v treatment. The Journal of Prevention of Alzheimer's Disease. 2024;1–15.
Blennow K, Galasko D, Perneczky R, Quevenco F, van der Flier WM, Akinwonmi A, et al. The
potential clinical value of plasma biomarkers in Alzheimer's Blennow K, Galasko D, Perneczky R, Quevenco F, van der Flier WM, Akinw
potential clinical value of plasma biomarkers in Alzheimer's disease. Alzhe
2023;19(12):5805–16.
Dubois B, Villain N, Schneider L, Fox N, Campbell N, G
- 18. potential clinical value of plasma biomarkers in Alzheimer's disease. Alzheimer's & Dementi

18. Dubois B, Villain N, Schneider L, Fox N, Campbell N, Galasko D, et al. Alzheimer disease as a

19. Dubois B, Villain N, S 2023;19(12):5805–16.
Dubois B, Villain N, Schneider L, Fox N, Campbell N, Galasko D, et al. Alzheimer disease as a
clinical-biological construct—an International Working Group recommendation. JAMA
neurology. 2024;
Hansson Dubois B, Villain N, Sch
clinical-biological const
neurology. 2024;
Hansson O, Edelmayer
Alzheimer's Association
disease. Alzheimer's &
- 19. Dubois B, Villain N, Schneider L, Fox N, Campbell N, Galasko D, et al. Alzheimer disease as a neurology. 2024;
Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, et al. The
Alzheimer's Association appropriate use recommendations for blood biomarkers in Alz
disease. Alzheimer's & Dementia. 202 Mansson O, Edeln
Alzheimer's Assoc
disease. Alzheime
Kodosaki E, Zette
assay of Alzheime
-
- Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzh
disease. Alzheimer's & Dementia. 2022;18(12):2669–86.
21. Kodosaki E, Zetterberg H, Heslegrave A. Validating blood tests as a possible ro Alzheimer's & Dementia. 2022;18(12):2669–86.
Kodosaki E, Zetterberg H, Heslegrave A. Validating blood tests as a possible routine diagnostic
assay of Alzheimer's disease. Expert Review of Molecular Diagnostics. 2023;23(12) Kodosaki E, Zetterberg H, Heslegrave A. Validating blood
assay of Alzheimer's disease. Expert Review of Molecular
Kivisäkk P, Carlyle BC, Sweeney T, Trombetta BA, LaCasse
for diagnosis of Alzheimer's disease and prediction 22. Kivisäkk P, Carlyle BC, Sweeney T, Trombetta BA, LaCasse K, El-Mufti L, et al. Plasma biomarker
22. Kivisäkk P, Carlyle BC, Sweeney T, Trombetta BA, LaCasse K, El-Mufti L, et al. Plasma biomarker
22. Kivisäkk P, Carlyl Assay of Alzheimer's disease and prediction of cognitive decline in individuals with mill cognitive impairment. Frontiers in neurology. 2023;14:1069411.
Simrén J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez
- 122. Simma B, Mattsson-Carling P, Schindler SE, Smith R, Ossenkoppele R, et al. Blooman
23. Simrén J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, et al. The diagnostic and
23. Simrén J, Leuzy A, Karikari For diagnositive impairment. Frontiers in neurology. 2023;14:1069411.
Simrén J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, et al. The diagnostic and
prognostic capabilities of plasma biomarkers in Alzhei
- Simrén J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodrig
prognostic capabilities of plasma biomarkers in Alzheimer's disea
2021;17(7):1145–56.
Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith
bioma 23. Simrén J, Leurs A, Mathemark, J, Leurs A, Leurs A, Mathemark, Baran, J. Leurs A, Benentia.
2021;17(7):1145–56.
24. Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, et al. Bloo
2024;33 2021;17(7):1145–56.
Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, et al. Blo
biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA.
2024;332(15):1245–57.
Vand Palmqvist S, Tideman
biomarkers to detect
2024;332(15):1245–5
VandeVrede L, Rabinc
Care? JAMA neurolog 224, 232. It is detect Alzheimer disease in primary care and secondary care. JAMA.
2024, 332. IS): 1245–57.
25. VandeVrede L, Rabinovici GD. Blood-Based Biomarkers for Alzheimer Disease—Ready for Primary
25. VandeVrede L,
- 2024;332(15):1245–57.
VandeVrede L, Rabinovici GD. Blood-Based Biomarkers for Alzheimer Disease—Read
Care? JAMA neurology. 2024;81(10):1030–1.
Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer's di VandeVrede L, Rabinovic
Care? JAMA neurology.
Hansson O, Blennow K, i
practice and trials. Natu
Li Y, Schindler SE, Bolling
-
- 25. Vande Vrede L, Rabinovici Care? JAMA neurology. 2024;81(10):1030–1.
26. Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer's disease in clinical
practice and trials. Nature aging. 2023;3(5):506 ET THE Hansson O, Blennow K, Zetterberg H, Dage J.

practice and trials. Nature aging. 2023;3(5):5(

Li Y, Schindler SE, Bollinger JG, Ovod V, Mawu

amyloid-β 42/40 for detecting Alzheimer dise

99. 27. Li Y, Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Weiner MW, et al. Validation of plasma
27. Li Y, Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Weiner MW, et al. Validation of plasma
28. Ankeny SE, Bacci J practice and trials. Nature aging. 2023;2(2):2022.2023
Li Y, Schindler SE, Bollinger JG, Ovod V, Mawuenyega
amyloid-β 42/40 for detecting Alzheimer disease am
99.
Ankeny SE, Bacci JR, Decourt B, Sabbagh MN, Mielke
Biomark
- amyloid- β 42/40 for detecting Alzheimer disease amyloid plaques. Neurology. 2022;98(7):e688–
99.
28. Ankeny SE, Bacci JR, Decourt B, Sabbagh MN, Mielke MM. Navigating the Landscape of Plasma
Biomarkers in Alzheimer's D amylon, princy to the account B, Sabbagh MN, Mielke MM. Navigating the Landscape of Plasma
Biomarkers in Alzheimer's Disease: Focus on Past, Present, and Future Clinical Applications.
Neurology and Therapy. 2024;1–17.
Cai ara
Ank
Bior
Neu
Cho 28. Ankeny SE, Backing Terms, 2022, 2024; Decours on Past, Present, and Future Clinical Applications.

Neurology and Therapy. 2024;1–17.

29. Cai H, Pang Y, Fu X, Ren Z, Jia L. Plasma biomarkers predict Alzheimer's disease
- Neurology and Therapy. 2024;1–17.
Cai H, Pang Y, Fu X, Ren Z, Jia L. Plasma biomarkers predict Alzheimer's disease before clinica
onset in Chinese cohorts. Nature Communications. 2023;14(1):6747.
Chen S, Huang Y, Shen X, G Cai H, Pang Y, Fu X, Ren Z, Jia L. Plasn
onset in Chinese cohorts. Nature Co
Chen S, Huang Y, Shen X, Guo Y, Tan I
tracks disease progression in Alzhein
- 2023;14(1):6747.
29. Chen S, Huang Y, Shen X, Guo Y, Tan L, Dong Q. Longitudinal plasma phosphorylated tau 181
2021; tracks disease progression in Alzheimer's disease. Transl Psychiatry. 2021; 11: 356. 2021; Chen S, Huang Y, Shen X, Guo Y, Tan L, Dong Q. Longitudinal plasma pl
tracks disease progression in Alzheimer's disease. Transl Psychiatry. 20
Tracks disease progression in Alzheimer's disease. Transl Psychiatry. 20 30. Chen S, Huang Y, Shen X, Guo Y, Huang Y, Tan C, Dong Q. Longitudinal plasma property, Shen Multiple tracks
tracks disease progression in Alzheimer's disease. Transl Psychiatry. 2021; 11: 356. 2021; tracks disease progression in Alzheimer's disease. Transl Psychiatry. 2021; 11: 356. 2021;

-
- 32. Matthews DC, Kinney JW, Ritter A, Andrews RD, Toledano Strom EN, Lukic AS, et al. Relationship
32. Matthews DC, Kinney JW, Ritter A, Andrews RD, Toledano Strom EN, Lukic AS, et al. Relationship
32. Matthews DC, Kinney Translational psychiatry. 2021;11(1):27.
Matthews DC, Kinney JW, Ritter A, Andrews RD, Toledano Strom EN, Lukic AS, et al. Relational between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate.
Alz Matthews DC, Kinney JW, Ritter A, Andro
between plasma biomarkers, tau PET, FI
Alzheimer's disease patients. Alzheimer
Interventions. 2024;10(3):e12490.
Stevenson-Hoare J, Heslegrave A, Leone
biomarkers and genetics in the between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate
Alzheimer's disease patients. Alzheimer's & Dementia: Translational Research & Clinical
Interventions. 2024;10(3):e12490.
33. Stevenson-Ho
- Alzheimer's disease patients. Alzheimer's & Dementia: Translational Research & Clinical
Interventions. 2024;10(3):e12490.
Stevenson-Hoare J, Heslegrave A, Leonenko G, Fathalla D, Bellou E, Luckcuck L, et al. Plas
biomarker Interventions. 2024;10(3):e12490.
Stevenson-Hoare J, Heslegrave A, Leonenko G, Fathalla D, Bellou E, Luckcuck L, et al. Plas
biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease. Brain.
2023;146(2
- Interventions. 2024; 1, Heslegrave A, L
Stevenson-Hoare J, Heslegrave A, L
2023;146(2):690–9.
Crean S, Ward A, Mercaldi CJ, Collir
prevalence in Alzheimer's disease p
literature review and meta-analysis biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease. Brain.

2023;146(2):690–9.

34. Crean S, Ward A, Mercaldi CJ, Collins JM, Cook MN, Baker NL, et al. Apolipoprotein E ε 4

prevalence in Al 8023;146(2):690–9.

Crean S, Ward A, Mercaldi CJ, Collins JM, Cook MN, Baker NL, et al. Apolipoprotein E εφ

prevalence in Alzheimer's disease patients varies across global populations: a systemat

literature review and m Crean S, Ward A, Me
prevalence in Alzhei
literature review and
30.
Vipin A, Kumar D, So
association between 34. Creative in Alzheimer's disease patients varies across global populations: a systematic
diterature review and meta-analysis. Dementia and geriatric cognitive disorders. 2011;32
30.
35. Vipin A, Kumar D, Soo SA, Zailan
- prevalence in Alzheimer's disease in Alzheimer's disease patients and the Vipin A, Kumar D, Soo SA, Zailan FZ, Leow YJ, Koh CL, et al. APOE4 carrier status determined association between white matter disease and grey matte dipliterature review and meta-analysis. Dementia and gerianistic regionals and consistent respectively. Depth
association between white matter disease and grey matter atrophy in early-stage dementia.
Alzheimer's Research & Vipi
asso
Alzh
EM,
Ava
alzh
- association between white matter disease and grey matter atrophy in early-stage dementia
Alzheimer's Research & Therapy. 2023;15(1):103.
36. EMA. Leqembi recommended for treatment of early Alzheimer's disease [Internet]. 2 Alzheimer's Research & Therapy. 2023;15(1):103.
EMA. Leqembi recommended for treatment of early Alzheimer's disease [Internet]. 2024.
Available from: https://www.ema.europa.eu/en/news/leqembi-recommended-treatment-early-st
- EMA. Leqembi recommended for treatment of ea
Available from: https://www.ema.europa.eu/en/n
alzheimers-disease
Qiu WQ, Zhu H, Dean M, Liu Z, Vu L, Fan G, et al. A
allele: longitudinal follow-up for the development
of geria Available from: https://www.ema.europa.eu/en/news/leqembi-recommended-treatment
alzheimers-disease
37. Qiu WQ, Zhu H, Dean M, Liu Z, Vu L, Fan G, et al. Amyloid-associated depression and ApoE
allele: longitudinal follow-up Qiu WQ, Zhu H, Dea
allele: longitudinal f
of geriatric psychiat
Pomara N, Bruno D,
dynamics in late-life
2022;12(1):301.
- dynamics in late-life major depression: a longitudinal study. Translational Psychiatry.
2022;12(1):301. allele: longitudinal follow-up for the development of Alzheimer's disease. International journ
of geriatric psychiatry. 2016;31(3):316–22.
38. Pomara N, Bruno D, Plaska CR, Ramos-Cejudo J, Osorio RS, Pillai A, et al. Plas allele: longitudinal formula for the development of geriatric psychiatry. 2016;31(3):316–22.

Pomara N, Bruno D, Plaska CR, Ramos-Cejudo J, Osorio RS, Pillai A, et al. Plasma Amyloid-β

dynamics in late-life major depressi
- Pomara N, Bruno D, Plaska CR, Ramos-Ceju
dynamics in late-life major depression: a lo
2022;12(1):301.
Blasko I, Kemmler G, Jungwirth S, Wichart I
42 independently predicts both late-onset
Journal of Geriatric Psychiatry. 2 39. Blasko I, Kemmler G, Jungwirth S, Wichart I, Krampla W, Weissgram S, et al. Plasma amyloid
39. Blasko I, Kemmler G, Jungwirth S, Wichart I, Krampla W, Weissgram S, et al. Plasma amyloid-82 independently predicts both depression, and dementia in community-dwelling elderly. Journal of psychiatric research and Alzheimer disease. The Arabian depression: and Alzheimer disease. The Arabian depression and Alzheimer disease. The Arabian depres Blasko I, Kemmle
21 independentl
22 independentl
Journal of Geriat
Direk N, Schrijve
depression, and
2013;47(4):479–
- 12 independently predictive, 2010;18(11):973–82.

Direk N, Schrijvers EM, de Bruijn RF, Mirza S, Hofman A, Ikram MA, et al. Plasma amyloid β,

depression, and dementia in community-dwelling elderly. Journal of psychiatric
- 41. Krell-Roesch J, Zaniletti I, Syrjanen JA, Kremers WK, Algeciras-Schimnich A, Dage JL, et al.
Plasma-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: A Direk N, Schrijvers EM, de Bruijn RF, Mirza S, Hofman
depression, and dementia in community-dwelling ele
2013;47(4):479–85.
Krell-Roesch J, Zaniletti I, Syrjanen JA, Kremers WK, A
Plasma-derived biomarkers of Alzheimer's d depression, and dementia in community-dwelling elderly. Journal of psychiatric research.

2013;47(4):479–85.

41. Krell-Roesch J, Zaniletti I, Syrjanen JA, Kremers WK, Algeciras-Schimnich A, Dage JL, et al.

Plasma-derived 2013;47(4):479–85.
2013;47(4):479–85.
Krell-Roesch J, Zaniletti I, Syrjanen JA, Kremers WK, Algeciras-Schimnich A, Dage JL, et al.
Plasma-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: A
community Xrell-Roesch J, Zanile
Plasma-derived bion
community-based st
2023;15(3):e12461.
Huang L, Huang Q, X
association with plas Plasma-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: A
community-based study. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Mon
2023;15(3):e12461.
42. Huang L, Huang Q, Xie F, Guo Q. Ne
-
- community-based study. Alzheimer's & Dementia: Diagnosis, Assessment & Disease M
2023;15(3):e12461.
Huang L, Huang Q, Xie F, Guo Q. Neuropsychiatric symptoms in Alzheimer's continuum
association with plasma biomarkers. Jou 2023;15(3):e12461.
Huang L, Huang Q, Xie F, Guo Q. Neuropsychiatric symptoms in Alzheimer's continuum and their
association with plasma biomarkers. Journal of Affective Disorders. 2024;348:200–6.
Steinacker P, Al Shweiki M 2023;15(3):e12461. association with plasma biomarkers. Journal of Affective Disorders. 2024;348:200–6.
43. Steinacker P, Al Shweiki MR, Oeckl P, Graf H, Ludolph AC, Schönfeldt-Lecuona C, et al. Glial
fibrillary acidic protein as blood biomar Steinacker P, Al Shweiki MR, Oeckl P, Graf H, Ludolph AC, Schönfeldt-Lecuona C, et al.
fibrillary acidic protein as blood biomarker for differential diagnosis and severity of m
depressive disorder. Journal of psychiatric r fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major
depressive disorder. Journal of psychiatric research. 2021;144:54–8.
The AC, Schönfeld AC, Schönfeldt-Records-R. depressive disorder. Journal of psychiatric research. 2021;144:54-8. depressive disorder. Journal of psychiatric research. 2021;144:54–8.
- $\frac{1}{2}$
- impairment–neuropsychiatric symptoms on the Alzheimer's continuum. Journal of geriatric
psychiatry and neurology. 2022;35(3):434–41.
45. Naude JP, Gill S, Hu S, McGirr A, Forkert ND, Monchi O, et al. Plasma neurofilament l psychiatry and neurology. 2022;35(3):434–41.
Naude JP, Gill S, Hu S, McGirr A, Forkert ND, Monchi O, et al. Plasma neurofilament light: a
marker of neurodegeneration in mild behavioral impairment. Journal of Alzheimer's di psychiatry and neurology. 2022, 2022.

Naude JP, Gill S, Hu S, McGirr A, Forkert ND, M.

marker of neurodegeneration in mild behavior

2020;76(3):1017–27.

Petersen RC. Mild cognitive impairment as a di

2004;256(3):183–94
-
- marker of neurodegeneration in mild behavioral impairment. Journal of Alzheimer's diseas
2020;76(3):1017–27.
46. Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of internal medicine.
2004;256(3):183– 2020;76(3):1017–27.
Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of internal medicine.
2004;256(3):183–94.
Jack Jr CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA rese Petersen RC. Mild cog
2004;256(3):183–94.
Jack Jr CR, Bennett DA
framework: toward a
2018;14(4):535–62. 2004;256(3):183–94.

47. Jack Jr CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA researc

framework: toward a biological definition of Alzheimer's disease. Alzheimer's & dementia.

2018;14(4):5 Jack Jr CR, Bennett DA
Framework: toward a
2018;14(4):535–62.
Leow Y, Wang J, Vipin
Singapore (BIOCIS): Pi
of Alzheimer's Diseas
- framework: toward a biological definition of Alzheimer's disease. Alzheimer's & dementia.
2018;14(4):535–62.
48. Leow Y, Wang J, Vipin A, Sandhu G, Soo S, Kumar D, et al. Biomarkers and Cognition Study,
Singapore (BIOCIS): 2018;14(4):535–62.
Leow Y, Wang J, Vipin A, Sandhu G, Soo S, Kumar D, et al. Biomarkers and Cognition Study,
Singapore (BIOCIS): Protocol, Study Design, and Preliminary Findings. The Journal of Prever
of Alzheimer's Disea
- Example 2018

Leow Y, Wang J, Vipi

Singapore (BIOCIS): I

of Alzheimer's Disea

Pendlebury ST, Poole

genotype and deme

cohort study. Stroke 48. Leongong (BIOCIS): Protocol, Study Design, and Preliminary Findings. The Journal of Prevention Alzheimer's Disease. 2024;1–13.
49. Pendlebury ST, Poole D, Burgess A, Duerden J, Rothwell PM, Oxford Vascular Study. APOE-Singapore (BIOCIS): Protocol, Study 2014; Protocol, Study Design, Study Designed Study APOE-E4
Singlebury ST, Poole D, Burgess A, Duerden J, Rothwell PM, Oxford Vascular Study. APOE-E4
genotype and dementia before and afte Pendlebury ST, Poole D, Burgess A, I
genotype and dementia before and
cohort study. Stroke. 2020;51(3):75
Zhong L, Xie YZ, Cao TT, Wang Z, Wa
genotyping apolipoprotein E gene p
-
- 49. genotype and dementia before and after transient ischemic attack and stroke: population-ba

49. cobort study. Stroke. 2020;51(3):751–8.

50. Zhong L, Xie YZ, Cao Π, Wang Z, Wang T, Li X, et al. A rapid and cost-effect genotype and y. Stroke. 2020;51(3):751–8.
Zhong L, Xie YZ, Cao TT, Wang Z, Wang T, Li X, et al. A rapid and cost-effective method for
genotyping apolipoprotein E gene polymorphism. Molecular neurodegeneration. 2016;11:1–8. Entre study. Stroke. 2020; 2020.
2hong L, Xie YZ, Cao TT, Wang Z, Wang T,
genotyping apolipoprotein E gene polyn
Wilson DH, Rissin DM, Kan CW, Fournier
analyzer: a novel fully automated digital
and multiplexing. Journal of Solution 2016;11

S1. Wilson DH, Rissin DM, Kan CW, Fournier DR, Piech T, Campbell TG, et al. The Simoa HD-1

analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sens

and multiplexing. Jour genotyping apolitics of the polymorphism. Wilson DH, Rissin DM, Kan CW, Fournier DR, Piech T, Campbell TG, et al. The Simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivi
- analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sen
and multiplexing. Journal of laboratory automation. 2016;21(4):533–47.
52. Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J and multiplexing. Journal of laboratory automation. 2016;21(4):533–47.
Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J. Plasma biomarkers as predictors of
outcome in patients with advanced hepatocellular carcin
- and Multiplexing. Journal Multiplexing. Very Multiplexing. Very Multiplexing. University. Plasma biom outcome in patients with advanced hepatocellular carcinoma. Clinical Ca
2012;18(8):2290–300.
Nixon AB, Pang H, Starr MD, 52. List 1992. Hotel, Peña Ce, Lathia Ce, Lathia Ce, Lathia Contome in patients with advanced hepatocellular carcinoma. Clinical Cancer Research.

53. Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, et 2012;18(8):2290–300.
Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, et al. Prognostic
predictive blood-based biomarkers in patients with advanced pancreatic cancer: results
CALGB80303 (Alliance). Clin Vallam Chang H, Starn

1912: The Pang H, Starn

1920–2012: Predictive blood-based

1920

2012: Carolian Cangles Carolic

1930

1930-2013: Startegies: understandi

1930: understandi

1930: understandi

1930: understandi

19
- Franchine Blood-based biomarkers in patients with advanced pancreatic cancer: results from
CALGB80303 (Alliance). Clinical Cancer Research. 2013;19(24):6957–66.
54. Gao W, Yan X, Yuan J. Neural correlations between cogniti CALGB80303 (Alliance). Clinical Cancer Research. 2013;19(24):6957–66.
Gao W, Yan X, Yuan J. Neural correlations between cognitive deficits and emotion regulation
strategies: understanding emotion dysregulation in depressio
- Gao W, Yan X, Yuan J. Neural correlations between cognitive deficits and
strategies: understanding emotion dysregulation in depression from the
control and cognitive biases. Psychoradiology. 2022;2(3):86–99.
Hack LM, Tozzi 54. Gao W, Wanter and Constrained The Magnetic Definition of the perspective of cognition
trol and cognitive biases. Psychoradiology. 2022;2(3):86–99.
55. Hack LM, Tozzi L, Zenteno S, Olmsted AM, Hilton R, Jubeir J, et al. standing emanuation diversions. Psychoradiology. 2022;2(3):86–99.

Hack LM, Tozzi L, Zenteno S, Olmsted AM, Hilton R, Jubeir J, et al. A cognitive biotype of

depression and symptoms, behavior measures, neural circuits, an Hack LM, Tozzi L, Zenteno S, Olmsted AM, Hilton R, Jubeir J, et aldepression and symptoms, behavior measures, neural circuits, a
outcomes: a Prespecified secondary analysis of a randomized cli
2023;6(6):e2318411-e2318411.
 depression and symptoms, behavior measures, neural circuits, and differential treatmen
outcomes: a Prespecified secondary analysis of a randomized clinical trial. JAMA Networ
2023;6(6):e2318411-e2318411.
56. Lupien SJ, Mah
- outcomes: a Prespecified secondary analysis of a randomized clinical trial. JAMA Network
2023;6(6):e2318411–e2318411.
Lupien SJ, Maheu F, Tu M, Fiocco A, Schramek TE. The effects of stress and stress hormone
human cognitio 2023;6(6):e2318411–e2318411.
Lupien SJ, Maheu F, Tu M, Fiocco A, Schramek TE. The effects of stress and stress hormones on
human cognition: Implications for the field of brain and cognition. Brain and cognition.
2007;65(3) 2023;67(2):20221-1221-1221-1221-1221
Lupien SJ, Maheu F, Tu M, Fiocco
human cognition: Implications fo
2007;65(3):209–37. 56. Lupien SJ, Maheu F, Tu M, Fiocco A, Schramek TE. The effects of stress and stress hormones on $h_{1,2007;65(3);209-37.}$ implications for the field of brain and cognition. Brain and cognition. Brain and cognition. Brain and cognition. Brain and complex $\mathcal{L} = \mathcal{L} \cup \mathcal{L}$ 2007
- **.**
.
- and neuropathological diagnoses of Alzheimer disease and related dementias. JAMA psychiatr
2022;79(4):359–67.
58. Dietlin S, Soto M, Kiyasova V, Pueyo M, de Mauleon A, Delrieu J, et al. Neuropsychiatric symptoms and risk o 2022;79(4):359–67.
Dietlin S, Soto M, Kiyasova V, Pueyo M, de Mauleon A, Delrieu J, et al. Neuropsychiatric
symptoms and risk of progression to Alzheimer's disease among mild cognitive impairment
subjects. Journal of Alzhe Dietlin S, Soto M, Kiy
Symptoms and risk c
subjects. Journal of ,
Guan DX, Rehman T,
symptoms: Risk facte
Alzheimer's disease
- symptoms and risk of progression to Alzheimer's disease among mild cognitive impairm
subjects. Journal of Alzheimer's Disease. 2019;70(1):25–34.
59. Guan DX, Rehman T, Nathan S, Durrani R, Potvin O, Duchesne S, et al. Neur subjects. Journal of Alzheimer's Disease. 2019;70(1):25–34.
Guan DX, Rehman T, Nathan S, Durrani R, Potvin O, Duchesne S, et al. Neuropsychiatric
symptoms: Risk factor or disease marker? A study of structural imaging biom
- Suan DX, Rehman T, Nathan S, Durrani R, Potvin O, Duchesn
symptoms: Risk factor or disease marker? A study of structu
Alzheimer's disease and incident cognitive decline. Human E
Lussier FZ, Pascoal TA, Chamoun M, Therriau 59. Guan Diversion: Risk factor or disease marker? A study of structural imaging biomarkers of
Alzheimer's disease and incident cognitive decline. Human Brain Mapping. 2024;45(13)
60. Lussier FZ, Pascoal TA, Chamoun M, Th Alzheimer's disease and incident cognitive decline. Human Brain Mapping. 2024;45(13
Lussier FZ, Pascoal TA, Chamoun M, Therriault J, Tissot C, Savard M, et al. Mild behavior
impairment is associated with β -amyloid but
- Lussier FZ, Pascoal TA, Chamoun M, Therriault J, Tissot C, Savard M, et al. Mild behavioral
impairment is associated with β-amyloid but not tau or neurodegeneration in cognitively intact
elderly individuals. Alzheimer's & impairment is associated with β -amyloid but not tau or neurodegeneration in cognitively i
elderly individuals. Alzheimer's & dementia. 2020;16(1):192–9.
61. Piccinni A, Origlia N, Veltri A, Vizzaccaro C, Marazziti D, V implering individuals. Alzheimer's & dementia. 2020;16(1):192–9.
Piccinni A, Origlia N, Veltri A, Vizzaccaro C, Marazziti D, Vanelli F, et al. Neurodegeneration,
β-amyloid and mood disorders: state of the art and future p Piccinni A, Origlia N, Veltri A, Vizzaccaro C, Marazziti D, Vanelli F,

β-amyloid and mood disorders: state of the art and future persp

geriatric psychiatry. 2013;28(7):661–71.

Brown RB. Stress, inflammation, depression,
-
- 62. Brown RB. Stress, inflammation, depression, and dementia associated with phosphate toxic
62. Brown RB. Stress, inflammation, depression, and dementia associated with phosphate toxic
63. Plascencia-Villa G, Perry G. Ne geriatric psychiatry. 2013;28(7):661–71.
Brown RB. Stress, inflammation, depression, and dementia associated with phosphate toxicity.
Molecular Biology Reports. 2020;47(12):9921–9.
Plascencia-Villa G, Perry G. Neuropatholo Brown RB. Stress, inflammation, depress
Molecular Biology Reports. 2020;47(12):
Plascencia-Villa G, Perry G. Neuropatholo
Alzheimer disease and related dementia
2022;192(10):1340–6. 63. Plascencia-Villa G, Perry G. Neuropathologic changes provide insights into key mechanisms of
Alzheimer disease and related dementia. The American Journal of Pathology.
2022;192(10):1340–6.
64. Naude J, Wang M, Leon R, Morreams 2020; Meports. 2020; Meantal Biologic channels.

Alzheimer disease and related dementia. The Am

2022;192(10):1340–6.

Naude J, Wang M, Leon R, Smith E, Ismail Z. Tau-F

relation to mild behavioral impairment in o
- Frame disease and related dementia. The American Journal of Pathology.

2022;192(10):1340–6.

64. Naude J, Wang M, Leon R, Smith E, Ismail Z. Tau-PET in early cortical Alzheimer brain regions in

relation to mild behaviora 2022;192(10):1340–6.

Naude J, Wang M, Leon R, Smith E, Ismail Z. Tau-PET in early cortical Alzheime

relation to mild behavioral impairment in older adults with either normal cog

cognitive impairment. Neurobiology of Agi
- Naude J, Wang M, Leor
relation to mild behavior
cognitive impairment.
Tissot C, Therriault J, P;
regional tau pathology
Alzheimer's disease. Al relation to mild behavioral impairment in older adults with either normal cognition or mild
cognitive impairment. Neurobiology of Aging. 2024;138:19–27.
65. Tissot C, Therriault J, Pascoal TA, Chamoun M, Lussier FZ, Savard relative impairment. Neurobiology of Aging. 2024;138:19–27.
Tissot C, Therriault J, Pascoal TA, Chamoun M, Lussier FZ, Savard M, et al. Association betwe
regional tau pathology and neuropsychiatric symptoms in aging and d Cognia Compania Microsocies (γ 1926, 2029, 2024; 2022)
Tissot C, Therriault J, Pascoal TA, Chamoun M, Lussier FZ, Savarc
regional tau pathology and neuropsychiatric symptoms in aging
Alzheimer's disease. Alzheimer's & Dem For the passes Current opinion in neurobiology. 2020;61:116–24.

66. Walsh DM, Selkoe DJ. Amyloid β-protein and beyond: the path forward in Alzheimer's disease.

Current opinion in neurobiology. 2020;61:116–24.

67. Kim
-
- Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Intervertional 2021;7(1):e12154.
2021;7(1):e12154.
Walsh DM, Selkoe DJ. Amyloid β-protein and beyond: the path forward in Alzheimer's
Current 2021;7(1):e12154.
2021;7(1):e12154.
Walsh DM, Selkoe DJ. Amyloid β-protein and beyond: the path forward in Alzheimer's disease.
Current opinion in neurobiology. 2020;61:116–24.
Kim HJ, Park KW, Kim TE, Im JY, Shin HS, Kim Walsh DM, Selkoe I
Current opinion in
Kim HJ, Park KW, Ki
a diagnostic marke
2015;48(4):1043–5 Current opinion in neurobiology. 2020;61:116–24.

67. Kim HJ, Park KW, Kim TE, Im JY, Shin HS, Kim S, et al. Elevation of the plasma Aβ 40/Aβ 42 ratio

a diagnostic marker of sporadic early-onset Alzheimer's disease. Jou
- Current opinion in an enterting, exercise to the
Kim HJ, Park KW, Kim TE, Im JY, Shin HS, Kim S, et a
a diagnostic marker of sporadic early-onset Alzheir
2015;48(4):1043–50.
Janelidze S, Mattsson N, Palmqvist S, Smith R, B 68. Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in
Alzheimer's disease. Pournal of Alzheimer's Disease.
68. Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano 2015;48(4):1043–50.
Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in
Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and
longitudi
- Janelidze S, Mattsson
Alzheimer's disease: r
Iongitudinal progressi
Karikari TK, Pascoal TA
phosphorylated tau 1
prediction modelling Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology a
longitudinal progression to Alzheimer's dementia. Nature medicine. 2020;26(3):379–86.
69. Karikari TK, Pascoal TA, Ashton NJ, longitudinal progression to Alzheimer's dementia. Nature medicine. 2020;26(3):379–86.
Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood
phosphorylated tau 181 as a biomarker for Alzhei longitudinal progression to Alzheimer's demential change incontract 2020;20(2):2020 LM
Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood
phosphorylated tau 181 as a biomarker for Alzhe mosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic perform
prediction modelling study using data from four prospective cohorts. The Lancet Neu
2020;19(5):422–33. prediction modelling study using data from four prospective cohorts. The Lancet Neurology.
2020;19(5):422–33.
The Lancet Neurology. prediction modelling study using data from four prospective contact the Lancet Neurology. 2020;19(5):422–33.
- $\frac{1}{2}$ Initiative. Association of plasma neurofilament light with neurodegeneration in patients v
Alzheimer disease. JAMA neurology. 2017;74(5):557–66.
71. Brandebura AN, Paumier A, Onur TS, Allen NJ. Astrocyte contribution to dy
- Alzheimer disease. JAMA neurology. 2017;74(5):557–66.
Brandebura AN, Paumier A, Onur TS, Allen NJ. Astrocyte contribution to dysfunction, risk and
progression in neurodegenerative disorders. Nature Reviews Neuroscience. 20
- Brandebura AN, Paumier A, Onur TS, Allen NJ. Astrocyte oprogression in neurodegenerative disorders. Nature Revis
Hawksworth J, Fernandez E, Gevaert K. A new generation
Ageing research reviews. 2022;79:101654.
Simrén J, Elm
- progression in neurodegenerative disorders. Nature Reviews Neuroscience. 2023;24(1):23–39

72. Hawksworth J, Fernandez E, Gevaert K. A new generation of AD biomarkers: 2019 to 2021.

Ageing research reviews. 2022;79:101654 progression in the section of AD biomarkers: 2019 to 2021.
Ageing research reviews. 2022;79:101654.
Simrén J, Elmgren A, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease. Advance
in clinical chemistry. 2023
- 72. Hamksworth Persian Ageing research reviews. 2022;79:101654.

73. Simrén J, Elmgren A, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease. Adv

17. Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro Simrén J, Elmgren A, Blennow K, Zetterberg
in clinical chemistry. 2023;112:249–81.
Preische O, Schultz SA, Apel A, Kuhle J, Kae.
predicts neurodegeneration and clinical pro
Nature medicine. 2019;25(2):277–83. in clinical chemistry. 2023;112:249–81.

74. Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics

predicts neurodegeneration and clinical progression in presymptomatic Alzheimer
- Preische O, Schultz SA, Apel A, Kuhle J, I
predicts neurodegeneration and clinical
Nature medicine. 2019;25(2):277–83.
Cicognola C, Janelidze S, Hertze J, Zetter
glial fibrillary acidic protein detects Alzh
Alzheimer demen 2011;13:1–9.

The Communist Same Indianal Brogression in presymptomatic Alzheimer's disease.

Nature medicine. 2019;25(2):277–83.

The Communist Schultz S, Hertze J, Zetterberg H, Blennow K, Mattsson-Carlgren N, et al. Pla predicte in details neurodegeneration presents in present in present in predicts in an entity of the Coognola C, Janelidze S, Hertze J, Zetterberg H, Blennow K, Mattsson-Carlgren N, et al. Plasm
glial fibrillary acidic pro Cicognola C, Janelidze S, Hertze J, Zette
glial fibrillary acidic protein detects Alz
Alzheimer dementia in patients with n
2021;13:1–9.
Spotorno N, Najac C, Stomrud E, Matt:
Astrocytic function is associated with l glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to
Alzheimer dementia in patients with mild cognitive impairment. Alzheimer's research & therap
2021;13:1–9.
76. Spotorno N, Najac
- Alzheimer dementia in patients with mild cognitive impairment. Alzheimer's research & the
2021;13:1–9.
Spotorno N, Najac C, Stomrud E, Mattsson-Carlgren N, Palmqvist S, Van Westen D, et al.
Astrocytic function is associat 2021;13:1–9.
Spotorno N, Najac C, Stomrud E, Mattsson-Carlgren N, Palmqvist S, Van Westen D, et al.
Astrocytic function is associated with both amyloid-β and tau pathology in non-demented APOE
Metarriers. Brain Communicat Spotorno N, N
Spotorno N, N
Astrocytic fun
Macarriers. Br
Pereira JB, Jar
GFAP is an ear
2021;144(11);
- Astrocytic function is associated with both amyloid-β and tau pathology in non-demente

24 carriers. Brain Communications. 2022;4(3):fcac135.

77. Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teuni Astrocytic function is associated with the pathology in the continuation of the communications. 2022;4(3):fcac135.

Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, et al. Plasma

GFAP is Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, P
GFAP is an early marker of amyloid-β but not tau patho
2021;144(11):3505–16.
Preman P, Alfonso-Triguero M, Alberdi E, Verkhratsky A
disease: pathological significanc
-
- GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. Brain.
2021;144(11):3505–16.
78. Preman P, Alfonso-Triguero M, Alberdi E, Verkhratsky A, Arranz AM. Astrocytes in Alzheimer's
disease: pa (Apple 11):3505–16.
The Preman P, Alfonso-Triguero M, Alberdi E, Verkhratsky A, Arranz AM. Astrocytes in Alzheim
disease: pathological significance and molecular pathways. Cells. 2021;10(3):540.
Rauf A, Badoni H, Abu-Iznei Preman P, Alfonso-Trigue

disease: pathological sig

Rauf A, Badoni H, Abu-I;

markers: key indicators i

2022;27(10):3194. 78. Rauf A, Badoni H, Abu-Izneid T, Olatunde A, Rahman MM, Painuli S, et al. Neuroinflammatory
79. Rauf A, Badoni H, Abu-Izneid T, Olatunde A, Rahman MM, Painuli S, et al. Neuroinflammatory
79. Rauf A, Badoni H, Abu-Izneid Rauf A, Badoni H, Abu-Izneid T, Olatunde A, Rahman MM, Painuli S, et al. Neuroint
markers: key indicators in the pathology of neurodegenerative diseases. Molecule
2022;27(10):3194.
Cozza M, Boccardi V. A narrative review o 19. Rauf A, Badonia, The Linian C, Phalance A, Abuman A, Paintain C, Paintain March, 19.

2022;27(10):3194.

2022;27(10):3194.

20. Cozza M, Boccardi V. A narrative review on mild behavioural impairment: an exploration int
- markers: key indicators in the pathology of neurology and all alternative diseases.

Cozza M, Boccardi V. A narrative review on mild behavioural impairment: an explora

scientific perspectives. Aging clinical and experimen 2022;27(10):3194.

80. Cozza M, Boccardi V. A narrative review on mild behavioural impairment: an exploration into its

scientific perspectives. Aging clinical and experimental research. 2023;35(9):1807–21.

81. Fisher DW,
-
- scientific perspectives. Aging clinical and experimental research. 2023;35(9):1807–21.
81. Fisher DW, Dunn JT, Dong H. Distinguishing features of depression in dementia from primary
psychiatric disease. Discover Mental Hea Fisher DW, Dunn JT, Dong H. Distinguishing features of depression in dementia from pr
psychiatric disease. Discover Mental Health. 2024;4(1):3.
Jack Jr CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised 11. Fisher Dunney Dunney Martinguishing (1924;4(1):3.

82. Jack Jr CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagn

and staging of Alzheimer's disease: Alzheimer's Association Workg per and the subsected of the Mental Mental Health 2024;
and staging of Alzheimer's disease: Alzheimer's Associatio
Dementia. 2024;
Morella IM, Brambilla R, Morè L. Emerging roles of brain r
and neuropsychiatric disorders. and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's &
Dementia. 2024;
83. Morella IM, Brambilla R, Morè L. Emerging roles of brain metabolism in cognitive impairment
and neuropsychiatric diso
- Dementia. 2024;
Morella IM, Brambilla R, Morè L. Emerging roles of brain metabolism in cognitive impai
and neuropsychiatric disorders. Neuroscience & Biobehavioral Reviews. 2022;142:1048
Association Workgroup. Also be also ,
Morella IM, Bram
and neuropsychia
. 83. Morella IM, Brambin, Brambin, Morè L. Emerging roles of branch metabolism in cognition, printendient and neuropsychiatric disorders. Neuroscience & Biobehavioral Reviews. 2022;142:104892. and neuropsychiatric disorders. Neuroscience & Biobehavioral Reviews. 2022;142:104892.